ENCell Co

ENCell Co FCF/Debt

The Free Cash Flow to Debt Ratio of ENCell Co (456070.KQ) as of Oct 26, 2026 is -148.24 %. In the previous year, Free Cash Flow to Debt Ratio was -208.50 % — a change of -28.90% (higher).

FCF/Debt

-148.24 %

YoY

-28.90%

Last updated:

Free Cash Flow to Debt Ratio of ENCell Co is 2025 -148.24 % . Free Cash Flow to Debt Ratio of ENCell Co was 2024 -208.50 % . It decreases by -28.90% higher compared to the previous year.

The ENCell Co FCF/Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF/Debt
Date
FCF/Debt
Jan 1, 2021
-55.05 KRW
Jan 1, 2022
-43.33 KRW
Jan 1, 2023
-189.76 KRW
Jan 1, 2024
-208.50 KRW
Jan 1, 2025
-148.24 KRW
The ENCell Co FCF/Debt history
YEARFCF/DebtYoY
-148.24 %-28.90%
-208.50 %+9.87%
-189.76 %+337.94%
-43.33 %-21.28%
-55.05 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

ENCell Co Stock analysis

What does ENCell Co do? ENCell Co Ltd generates revenue through the development and research of cell and gene-based biopharmaceuticals, offering biopharmaceutical quality testing services, and providing biopharmaceutical consignment production. The company serves pharmaceutical and biotechnology firms requiring advanced drug development solutions and quality assurance. Its primary focus is on cell and gene therapies, with services tailored to support clients in the biopharmaceutical industry. The firm's offerings include research, testing, and production services for biopharmaceutical products. The company's core business model revolves around delivering specialized services to clients in the life sciences sector. It targets pharmaceutical companies and biotech firms seeking to develop and produce cell and gene-based treatments. ENCell's quality testing services ensure regulatory compliance and product safety, while its consignment production supports clients in scaling manufacturing without capital investment. These services collectively address key needs in the biopharmaceutical development lifecycle. ENCell Co Ltd's revenue streams are derived from research contracts, testing service fees, and consignment production agreements. The company's clients include pharmaceutical and biotechnology firms that outsource their biopharmaceutical development and production needs. By focusing on cell and gene-based therapies, ENCell positions itself as a specialized partner for clients navigating the complexities of modern biopharmaceutical innovation. ENCell Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ENCell Co stock

Free Cash Flow to Debt Ratio of ENCell Co is -148.24 % in 2025.

Free Cash Flow to Debt Ratio of ENCell Co changed from -208.50 % to -148.24 %, representing a -28.90% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow to Debt Ratio ENCell Co since 2006 – with annual values, charts, and detailed analysis.

FCF/Debt measures the percentage of total debt that could be repaid from free cash flow. It is a stricter measure than OCF/Debt as it accounts for capital expenditures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow to Debt Ratio's ENCell Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Leverage — ENCell Co

Debt-to-EquityNet Debt / EBITDAInterest CoverageCurrent RatioQuick RatioCash RatioDebt / AssetsFinancial LeverageEquity RatioLT Debt/EquityNet Debt/EquityDebt/EBITDADSCRFinancial Debt RatioOCF/DebtFCF/DebtNet Debt/FCFDebt/Market Cap

All Key Metrics — ENCell Co